Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this

PainSolve | Grünenthal
;

Join our community

By facilitating collaboration, we aim to increase disease understanding and co-develop new solutions for patients with pain.

Updates & Features

Stay up to date with analysis on the latest research

Paper of the Month

View our regular 'Paper of the Month' feature, in which we highlight recent publications of interest to the pain research community. In our latest feature, we look at 'Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment' by Tracey I, et al.
... Discover more

Listening to the patient – Surveys to accurately assess disease impact

The biopsychosocial consequences of pain are well documented but it remains inadequately managed for many patients. Research has shown that inadequate pain assessment is one of the most problematic barriers to achieving good pain control. This article highlights the importance of and difficulties in accurately measuring and assessing the patient experience of pain for understanding disease impact, making treatment decisions, and facilitating optimal outcomes.
... Discover more

“Pain is not a symptom: It's a disease in its own right and needs to be addressed with innovative treatments. At Grünenthal, we want to join forces with you to make a genuine difference in the life of patients affected by pain”

Gabriel Baertschi

Chairman of the Corporate Executive Board,
Chief Executive Officer

Like
 
Share

Share this with:

These are external links and will open in a new window